Free Trial

Nephros (NEPH) Stock Price, News & Analysis

Nephros logo
$4.03 -0.02 (-0.49%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$4.12 +0.09 (+2.11%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nephros Stock (NASDAQ:NEPH)

Key Stats

Today's Range
$4.02
$4.20
50-Day Range
$2.89
$5.00
52-Week Range
$1.36
$5.00
Volume
5,889 shs
Average Volume
55,150 shs
Market Capitalization
$42.72 million
P/E Ratio
33.58
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Buy

Company Overview

Nephros Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

NEPH MarketRank™: 

Nephros scored higher than 47% of companies evaluated by MarketBeat, and ranked 617th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nephros has only been the subject of 1 research reports in the past 90 days.

  • Read more about Nephros' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nephros is 33.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.75.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nephros is 33.58, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.26.

  • Price to Book Value per Share Ratio

    Nephros has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Nephros' valuation and earnings.
  • Percentage of Shares Shorted

    0.05% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nephros has recently increased by 21.05%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nephros does not currently pay a dividend.

  • Dividend Growth

    Nephros does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.05% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nephros has recently increased by 21.05%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Nephros has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Nephros this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Nephros insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.70% of the stock of Nephros is held by insiders.

  • Percentage Held by Institutions

    41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nephros' insider trading history.
Receive NEPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NEPH Stock News Headlines

Nephros Second Quarter 2025 Earnings: Beats Expectations
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
Nephros Announces Strong Second Quarter Financial Results
See More Headlines

NEPH Stock Analysis - Frequently Asked Questions

Nephros' stock was trading at $1.47 at the start of the year. Since then, NEPH shares have increased by 174.1% and is now trading at $4.03.

Nephros Inc. (NASDAQ:NEPH) issued its quarterly earnings results on Thursday, August, 7th. The company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05. The business had revenue of $4.40 million for the quarter, compared to analyst estimates of $3.60 million. Nephros had a net margin of 7.95% and a trailing twelve-month return on equity of 14.89%.
Read the conference call transcript
.

Nephros' top institutional investors include Topline Capital Management LLC (4.50%), Geode Capital Management LLC (0.88%) and Elkhorn Partners Limited Partnership (0.14%). Insiders that own company stock include Arthur H Amron and Robert R Jr Banks.
View institutional ownership trends
.

Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/07/2025
Today
8/28/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NEPH
CIK
1196298
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$5.00
Potential Upside/Downside
+36.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.12
Trailing P/E Ratio
33.58
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$70 thousand
Net Margins
7.95%
Pretax Margin
8.10%
Return on Equity
14.89%
Return on Assets
11.64%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.41
Quick Ratio
4.14

Sales & Book Value

Annual Sales
$14.16 million
Price / Sales
3.02
Cash Flow
$0.02 per share
Price / Cash Flow
202.39
Book Value
$0.91 per share
Price / Book
4.43

Miscellaneous

Outstanding Shares
10,600,000
Free Float
9,891,000
Market Cap
$42.72 million
Optionable
Not Optionable
Beta
1.11

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:NEPH) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners